Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28596741 | 0.89 | TDP1 (0.49) | TDP1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL18803863 | 0.84 | TDP1 (0.62) | TDP1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL22402374 | 0.83 | TDP1 (0.55) | TDP1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL26947300 | 0.83 | TDP1 (0.55) | TDP1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL26947353 | 0.83 | TDP1 (0.55) | TDP1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL9233936 | 0.81 | TDP1 (0.53) | TDP1RAB9ANPC1MEN1KMT2A | |
| Methyl Alcohol SCHEMBL28478479 | 0.80 | NPC1 (0.89) | TDP1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL25083241 | 0.79 | TDP1 (0.52) | TDP1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL12649200 | 0.79 | TDP1 (0.52) | TDP1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL12598389 | 0.79 | TDP1 (0.52) | TDP1RAB9ANPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027254-A | Isobutylene pyridine salt ionic polymer, preparation method and application thereof, and antibacterial high polymer material | 中国石油化工股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11712485-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11389464-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3939972-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | Molecular Insight Pharmaceuticals, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20220002663-A1 | SELECTIVE SALMONELLA OR E. COLI CULTIVATION METHOD, COMPOSITIONS AND USES | Solus Scientific Solutions Ltd (GB) | 2022-01-06 | — | — | US | disclosed |
| US-20210338850-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3545978-B1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARM INC (US) | 2021-09-08 | — | — | EP | disclosed |
| US-10898598-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| CN-108950645-B | Aluminum and aluminum alloy anodic oxidation nickel-free sealing agent | 上海铝通化学科技有限公司 | 2020-10-23 | — | — | CN | disclosed |
| EP-3719024-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | Mars, Incorporated (US) | 2020-10-07 | — | — | EP | disclosed |
| WO-2013022797-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS (US) | 2013-02-14 | — | — | WO | disclosed |
| US-20130034494-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS | 2013-02-07 | — | — | US | disclosed |
| US-20120149708-A1 | MODULATORS OF VIRAL TRANSCRIPTION, AND METHODS AND COMPOSITIONS THEREWITH | GEORGE MASON UNIVERSITY | 2012-06-14 | — | — | US | disclosed |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2012-05-24 | — | — | US | disclosed |
| WO-2012058065-A1 | BORONATES AS ARGINASE INHIBITORS | MARS INCORPORATED (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| WO-2012033525-A2 | P53-MDM2 ANTAGONISTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011133653-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20080096894-A1 | Anti-Bacterial Compounds | ASTON UNIVERSITY (GB) | 2008-04-24 | — | — | US | disclosed |
| US-20080096894-A1 | Anti-Bacterial Compounds | ASTON UNIVERSITY (GB) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130034494-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | KLK3, FOLH1, PSMA1 | TDP1 3701/4885RAB9A 514/4885NPC1 141/4885 |
| US-11389464-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | TDP1 1099/4885RAB9A 1827/4885NPC1 1758/4885 |
| US-20210338850-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | PSMA2, PSMA5, PSMA1 | TDP1 3120/4885RAB9A 1942/4885NPC1 1344/4885 |
| US-10898598-B2 | Triazine based radiopharmaceuticals and radioimaging agents | PSMA2, PSMA5, PSMA1 | TDP1 3120/4885RAB9A 1942/4885NPC1 1344/4885 |
| US-11712485-B2 | Triazine based radiopharmaceuticals and radioimaging agents | PSMA2, PSMA5, PSMA1 | TDP1 3120/4885RAB9A 1942/4885NPC1 1344/4885 |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | TDP1 1099/4885RAB9A 1827/4885NPC1 1758/4885 |
| US-20080096894-A1 | Anti-Bacterial Compounds | MRPL21, PGLS, FOSB | TDP1 3783/4885RAB9A 1952/4885NPC1 2717/4885 |
| US-20120149708-A1 | MODULATORS OF VIRAL TRANSCRIPTION, AND METHODS AND COMPOSITIONS THEREWITH | CDK2, CCNA1, CDK1 | TDP1 1939/4885RAB9A 3407/4885NPC1 2751/4885 |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | TDP1 1161/4885RAB9A 171/4885NPC1 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.